Objective
In the context of growing parasite resistance to drugs in malaria, new agents are needed to regain control on this deadly infection affecting mainly children. By a large screen, we uncovered that ravidasvir, licensed by the Egyptian company Pharco and approved with support from DNDi as part of an affordable cure for hepatitis C, is active against asexual and sexual stages of Plasmodium falciparum. In the framework of this EDCTP3 program, we aim to clinically validate the ability of ravidasvir to clear parasites thereby preventing disease resurgence and blocking transmission. The Ravidasvir Against Malaria Parasites (RAMP) project has 3 objectives: assess the efficacy of ravidasvir at reducing parasite carriage and block transmission to Anopheles, assess the ability of ravidasvir to complement Artemisinin-based Combination Therapies (ACT) to sustainably cure patients, and assess perception and compliance of anti-transmission drugs/drug combinations across different countries to inform elimination programs. Drug safety, possible drug-drug interactions and resistance markers will be scrutinized. Our strong, synergistic African - European consortium will initially test ravidasvir as a monotherapy in asymptomatic adults carrying gametocytes in Gabon. We will then evaluate ravidasvir co-administered with a WHO-recommended ACT in adults with uncomplicated malaria attacks in Mali. We will finally perform a non-inferiority Phase 3 trial in Ghana, Gabon, Mali and Uganda, with age de-escalation to rapidly but safely reach African children where artemisinin resistance will be or is already present. RAMP can rapidly repurpose ravidasvir for malaria, based on its promising, physiologically relevant dual activity in vitro. This cost-effective oral drug, devoid of severe side effects when administered for 12 weeks in hepatitis C, has a very strong potential to be safely co-administered for 3 days with ACT as a protection against parasites resistant to artemisinin and partner drugs.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug safety
- medical and health sciences health sciences infectious diseases malaria
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.2.1 - Health
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-JU-GH-EDCTP3-2025-01-two-stage
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
75654 Paris
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.